Immunocytokines Platform Superagonist Activates T-cells and NK Cells to Fight Solid Tumors With Jens Hennecke SOTIO TRANSCRIPT
Manage episode 267899907 series 99915
Jens Hennecke, Chief Business Officer, SOTIO explains how this biotech company is developing the next generation of immunotherapies with a focus on a new compound called SO-C101 based on the cytokine IL-15, the key cytokine that activates T-cells and NK cells. In clinical trials, this drug, a modified IL-15 does not cause unwanted side effects like similar products to treat solid tumors and is a superagonist with a much better potency to activate memory T-cells, cytotoxic T-cells and NK cells.
#SOTIO #immunotherapies #IL15